Design
Review
Authors
Loading...
Urges heightened CV safety monitoring in cancer therapy amid FDA constraints; leaves open optimal surveillance strategies.
Richard C. Becker (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: